crysvita
kyowa kirin holdings b.v. - burosumabs - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - zāles kaulu slimību ārstēšanai - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
asa-grindeks 500 mg tabletes
grindeks, as, latvia - skābes acetylsalicylicum - tablete - 500 mg
neomidantan 100 mg cietās kapsulas
olainfarm, as, latvia - amantadīna hidrohlorīds - kapsula, cietā - 100 mg
doxy-m-ratiopharm 100 mg tabletes
ratiopharm gmbh, germany - doksiciklīns - tablete - 100 mg
quiflox
krka, d.d., novo mesto, slovēnija - marbofloxacin - tabletes - 20 mg - suņi
quiflox
krka, d.d., novo mesto, slovēnija - marbofloxacin - tabletes - 80 mg - suņi
jodoxid 200 mg vaginālie supozitoriji
as Ņižfarm pārstāvniecība, latvija - povidons, jodēts - pesārijs - 200 mg
hexicon 16 mg vaginālie supozitoriji
as Ņižfarm pārstāvniecība, latvia - hlorheksidīna diglikonāts - pesārijs - 16 mg
perindopril zentiva 5 mg apvalkotās tabletes
zentiva, k.s., czech republic - perindoprila arginīns - apvalkotā tablete - 5 mg
perindopril zentiva 10 mg apvalkotās tabletes
zentiva, k.s., czech republic - perindoprila arginīns - apvalkotā tablete - 10 mg